BST:GB8A

Stock Analysis Report

Executive Summary

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Generex Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GB8A's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-18.7%

GB8A

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

-59.2%

GB8A

-13.5%

DE Biotechs

-20.9%

DE Market

Return vs Industry: GB8A underperformed the German Biotechs industry which returned -12.7% over the past year.

Return vs Market: GB8A underperformed the German Market which returned -20.6% over the past year.


Shareholder returns

GB8AIndustryMarket
7 Day-18.7%-0.7%-0.6%
30 Day-50.9%-7.8%-16.6%
90 Day-42.4%-21.1%-26.0%
1 Year-59.2%-59.2%-13.3%-13.5%-18.6%-20.9%
3 Year82.3%82.3%14.1%12.9%-19.0%-25.8%
5 Yearn/a-9.6%-11.9%-21.1%-31.8%

Price Volatility Vs. Market

How volatile is Generex Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Generex Biotechnology undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Generex Biotechnology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Generex Biotechnology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of GB8A’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Generex Biotechnology regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Generex Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

55.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Generex Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Generex Biotechnology performed over the past 5 years?

-3.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GB8A is currently unprofitable.

Growing Profit Margin: GB8A is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GB8A is unprofitable, and losses have increased over the past 5 years at a rate of -3.2% per year.

Accelerating Growth: Unable to compare GB8A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GB8A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: GB8A has a negative Return on Equity (-820.14%), as it is currently unprofitable.


Next Steps

Financial Health

How is Generex Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: GB8A's short term assets ($1.9M) do not cover its short term liabilities ($37.6M).

Long Term Liabilities: GB8A's short term assets ($1.9M) do not cover its long term liabilities ($10.5M).


Debt to Equity History and Analysis

Debt Level: GB8A's debt to equity ratio (294.4%) is considered high.

Reducing Debt: Insufficient data to determine if GB8A's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: GB8A has a low level of unsold assets or inventory.

Debt Coverage by Assets: GB8A's debt is not covered by short term assets (assets are 0.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if GB8A has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GB8A has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Generex Biotechnology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GB8A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GB8A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GB8A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GB8A's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GB8A's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Joe Moscato (55yo)

3.25s

Tenure

US$103,144

Compensation

Mr. Joseph Moscato, also known as Joe, has been the Chief Executive Officer, President and Chairman of the Board at Generex Biotechnology Corporation since January 18, 2017. Since 2009, Mr. Moscato has bee ...


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Moscato
CEO, President & Chairman of the Board3.25yrsUS$103.14k0.56% $162.4k
Mark Corrao
CFO & Treasurer3.25yrsUS$37.43kno data
Terry Thompson
Chief Operating Officer2.25yrsUS$1.54mno data
Andrew Ro
Chief Investment Officer3.25yrsUS$24.20kno data
Anthony Crisci
Chief Legal Officer0.67yrUS$822.04kno data
Anthony Dolisi
Chief Commercial Officer1.42yrsUS$819.83kno data
Jason Terrell
Chief Scientific Officer & Chief Medical Officer3.25yrsno datano data
Michelle Starr
Chief Marketing Officer1.42yrsno datano data
Richard Purcell
Executive Vice-President of Research & Drug Developmentno dataUS$68.33kno data
Marshal Shichtman
Executive VP & General Counsel1.17yrsno datano data

2.3yrs

Average Tenure

55yo

Average Age

Experienced Management: GB8A's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joseph Moscato
CEO, President & Chairman of the Board3.25yrsUS$103.14k0.56% $162.4k
Andrew Ro
Chief Investment Officer3.25yrsUS$24.20kno data
Gerald Bernstein
Member of Scientific Advisory Board19.25yrsUS$180.00kno data
Brian McGee
Independent Director16.08yrsUS$2.20kno data
Lawrence Salvo
Director3.25yrsno data0.57% $166.3k
Craig Eagle
Independent Director3.25yrsUS$2.20kno data
James Anderson
Independent Director8.83yrsUS$48.40kno data
Mark Prioletti
Independent Director1yrno data0.0064% $1.9k

3.3yrs

Average Tenure

62yo

Average Age

Experienced Board: GB8A's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 94.7%.


Top Shareholders

Company Information

Generex Biotechnology Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Generex Biotechnology Corporation
  • Ticker: GB8A
  • Exchange: BST
  • Founded: 1983
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$31.297m
  • Listing Market Cap: US$29.009m
  • Shares outstanding: 78.22m
  • Website: https://www.generex.com

Number of Employees


Location

  • Generex Biotechnology Corporation
  • 10102 USA Today Way
  • Suite 200
  • Miramar
  • Florida
  • 33025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNBTOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 1998
GB8ABST (Boerse-Stuttgart)YesCommon StockDEEURFeb 1998

Biography

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle kits with surgical plates, screws, and tools; and distributes surgical supplies, orthopedic implants, and biologics, including human placental derived tissue products for regenerative medicine applications. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/05 23:35
End of Day Share Price2020/04/03 00:00
Earnings2020/01/31
Annual Earnings2019/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.